Strides’ biologics arm Stelis Biopharma announced that it has obtained a positive CHMP recommendation for its first biosimilar product Kauliv™ (teriparatide, biosimilar to Eli Lily’s Forsteo®) for the treatment of osteoporosis.
Kualiv is the first biosimilar product developed in house by Stelis. Stelis will make Kualiv, which it has already licensed across 20 countries, in Bangalore. According to the announcement, the product “will generate incremental revenues for the Company starting FY24”.
Stelis is developing teriparatide, insulin glargine (biosimilar to Sanofi’s Lantus®), insulin lispro (biosimilar to Eli-Lilly’s Humalog®), insulin aspart (biosimilar to NovoNordisk’s Novolog®) and another “recently filed peptide for diabetes”.Print Page Mail Article